NHS patients denied new lung cancer drug after another NICE deadlockCertain untreated lung cancer patients on England’s NHS will have to make do with older drugs after NICE Share XNHS patients denied new lung cancer drug after another NICE deadlockhttps://pharmaphorum.com/news/nice-deadlock/
AstraZeneca commits to being carbon negative by 2030AstraZeneca has announced its ambition to have zero carbon emissions from its global operations by 2025 and to Share XAstraZeneca commits to being carbon negative by 2030https://pharmaphorum.com/news/astrazeneca-commits-to-being-carbon-negative-by-2030/
The three biggest challenges in lung cancer, and how researchers are tackling themDespite new paradigm-shifting treatments, lung cancer remains a deadly disease – and improving outcomes requires more than just Share XThe three biggest challenges in lung cancer, and how researchers are tackling themhttps://pharmaphorum.com/views-and-analysis/the-three-biggest-challenges-in-lung-cancer-and-how-researchers-are-tackling-them/
AZ and MSD’s Lynparza gets fast prostate cancer FDA reviewThe FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the Share XAZ and MSD’s Lynparza gets fast prostate cancer FDA reviewhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-fast-prostate-cancer-fda-review/
MiNA’s gene-activating tech wins an AstraZeneca allianceUK biotech MiNA Therapeutics’ RNA-based gene-activating technology has caught the eye of big pharma AstraZeneca. AZ has teamed Share XMiNA’s gene-activating tech wins an AstraZeneca alliancehttps://pharmaphorum.com/news/minas-gene-activating-tech-wins-an-astrazeneca-alliance/
AstraZeneca kicks off 2020 with double win in US and ChinaAstraZeneca has started 2020 strongly, with the FDA granting a fast review for its big-selling Farxiga in heart Share XAstraZeneca kicks off 2020 with double win in US and Chinahttps://pharmaphorum.com/news/astrazeneca-kicks-off-2020-with-double-win-in-us-and-china/
AZ, Merck add pancreatic cancer to Lynparza’s growing use listAstraZeneca and Merck & Co have cemented their lead in the PARP inhibitor class with FDA approval for Share XAZ, Merck add pancreatic cancer to Lynparza’s growing use listhttps://pharmaphorum.com/news/az-merck-add-pancreatic-cancer-to-lynparzas-growing-use-list/
FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filingThe FDA has approved an advanced breast cancer drug from AstraZeneca and Daiichi Sankyo in super-quick time. The Share XFDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filinghttps://pharmaphorum.com/news/fda-hastily-approves-daiichi-sankyo-azs-cancer-drug/
AZ sells ex-US rights to old cancer drugs Arimidex and CasodexFor several years AstraZeneca has been selling off rights to its older drugs to raise cash as it Share XAZ sells ex-US rights to old cancer drugs Arimidex and Casodexhttps://pharmaphorum.com/news/az-sells-ex-us-rights-to-old-cancer-drugs-arimidex-and-casodex/
